Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-95) and b) 4 pouches x 5 single-use containers (NDC 0078-0911-94), Rx Only, Manufactured by: The Ritedose Corporation Columbia, SC 29203; Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936.
Published June 15, 2022 · Recall initiated: May 10, 2022
Summary
FDA records drug Class III recall D-0984-2022, published June 15, 2022 and initiated May 10, 2022. Recalling firm: Novartis Pharmaceuticals Corporation; Status: Terminated; Reported quantity: 279,179 vials; Lot: Lot #: a) and b) 20DJ3, Exp. Date 03/2023. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications.
What to do
Voluntary: Firm initiated · Letter
Get an email if XIIDRA has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- XIIDRA
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Distributor
- Nationwide within the United States
- Lot
- Lot #: a) and b) 20DJ3, Exp. Date 03/2023.
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAXiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-useJune 15, 2022
- FDAXiidra (lifitegrast ophthalmic solution) 5%, packaged in a) 60 Single-Use Containers: 12 pouches x 5June 15, 2022
- FDAXiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2June 15, 2022
- FDAEthanol for Injection 95%, 67 mL Multi-Dose vial, Rx only, US Specialty Formulations, 1403 South AlbertJune 15, 2022
- FDAB-Complex + Chromic Chloride (Choline Chloride 3%, Inositol 3%, Pyridoxine HCl 2%, Niacinamide 2%, ThiamineJune 15, 2022
- FDANIM Vital Patient Interface 4.0 (P/N: NIM4CPB1) NIM with Software version 1.3.2June 8, 2022
Questions about this recall
Was Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-95) and b) 4 pouches x 5 single-use containers (NDC 0078-0911-94), Rx Only, Manufactured by: The Ritedose Corporation Columbia, SC 29203; Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936. recalled?
Yes. FDA published recall D-0984-2022 on June 15, 2022. Reported hazard: Failed Impurities/Degradation Specifications.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: XIIDRA.